ONC
BeOne Medicines AG
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+50/100
Last price
363.92
▲ 1.14 (0.31%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
360.68
Prev close
362.78
Day high
367.57
Day low
359.57
Volume
71.71K
Market cap
$41.40B
P/E (TTM)
65.10
52W range
253.95 – 385.22
Day trading desk
Gap from prior close
-0.58%
Prior close 362.78
VWAP
363.62
+0.08% from price
Relative volume
0.18×
Quiet session
Session range
2.23%
359.57 – 367.57
Position in range
54%
Mid range
ATR (14D)
9.28
2.55% of price
Prior day high
368.40
PDH
Prior day low
359.10
PDL
Bid / ask spread
—
Quote not published
Session volume
71.64K
Avg 391.40K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-0.55%
-2.5%
1M
+3.54%
+2.0%
3M
+20.17%
+16.7%
6M
+16.57%
+1.6%
YTD
+19.79%
+5.8%
1Y
+5.63%
-10.1%
3Y
+103.88%
+21.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ONC open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-357.46K
Net selling
Buy transactions
10
581.25K shares
Sell transactions
36
938.71K shares
Net transactions
+46
Buys less sells
Sell : buy shares
1.6 : 1
Mixed
Insider-held shares
19.64M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 1, 26 | BALL TITUS BENJAMIN Officer |
SELL | 132 | $46.97K | Direct |
| Aug 25, 26 | WU XIAOBIN President |
SELL | 280 | $106.40K | Direct |
| Aug 12, 26 | OYLER JOHN VICTOR Chief Executive Officer |
SELL | 240.81K | $86.48M | Direct |
| Aug 11, 26 | LEE CHAN HENRY General Counsel |
CONVERSION | 2.67K | $510.19K | Direct |
| Aug 11, 26 | LEE CHAN HENRY General Counsel |
SELL | 2.67K | $959.76K | Direct |
| Aug 3, 26 | ROSENBERG AARON Chief Financial Officer |
SELL | 1.16K | $361.81K | Direct |
| Jul 30, 26 | LEE CHAN HENRY General Counsel |
SELL | 1.04K | $337.93K | Direct |
| Jul 22, 26 | LEE CHAN HENRY General Counsel |
CONVERSION | 1.67K | $319.74K | Direct |
| Jul 22, 26 | LEE CHAN HENRY General Counsel |
SELL | 1.67K | $542.42K | Direct |
| Jul 21, 26 | OYLER JOHN VICTOR Chief Executive Officer |
SELL | 109.71K | $34.59M | Direct |
| Jul 20, 26 | OYLER JOHN VICTOR Chief Executive Officer |
CONVERSION | 33.99K | $4.08M | Direct |
| Jul 17, 26 | OYLER JOHN VICTOR Chief Executive Officer |
CONVERSION | 64.63K | $7.75M | Direct |
| Jul 17, 26 | OYLER JOHN VICTOR Chief Executive Officer |
SELL | 64.63K | $20.16M | Direct |
| Jul 16, 26 | OYLER JOHN VICTOR Chief Executive Officer |
CONVERSION | 283.15K | $41.14M | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BAKER BROS ADVISORS L.P. |
Unknown | — | Sale |
BAKER BROTHERS LIFE SCIENCES, L.P. |
Unknown | — | Sale |
BALL TITUS BENJAMIN |
Officer | 0 | Sale |
DUGAN MARGARET |
Director | 0 | Sale |
LEE CHAN HENRY |
General Counsel | 0 | Conversion of Exercise of derivative security |
RIVA ALESSANDRO |
Director | 0 | Sale |
ROSENBERG AARON |
Chief Financial Officer | 0 | Sale |
SANDERS CORAZON CORSEE D |
Director | 0 | Sale |
WANG LAI |
Officer | 0 | Sale |
WU XIAOBIN |
President | 16.36K | Sale |
Fundamentals
Market cap$41.40B
Enterprise value$38.20B
Revenue (TTM)$6.13B
Gross profit$5.45B
EBITDA$1.07B
Net income$655.71M
EPS (TTM)$5.59
Free cash flow$879.02M
Total cash$5.10B
Total debt$2.05B
Book value / share$45.78
Shares outstanding104.92M
Float80.96M
Short % of float2.11%
Dividend yield0.00%
Beta (5Y)0.61
Valuation & profitability ratios
Trailing P/E65.10
Forward P/E35.48
PEG ratio0.77
Price / sales—
Price / book7.95
EV / revenue6.23
EV / EBITDA35.65
Gross margin88.89%
Operating margin19.06%
Profit margin10.70%
Return on equity14.66%
Return on assets7.46%
Debt / equity39.61
Current ratio3.41
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $5.34B | $3.81B | $2.46B | $1.42B | +40.2% |
| Operating revenue | $6.79B | $4.81B | $2.98B | $1.59B | +41.1% |
| Cost of revenue | $668.54M | $594.09M | $379.92M | $286.48M | +12.5% |
| Gross profit | $4.67B | $3.22B | $2.08B | $1.13B | +45.3% |
| Research & development | $2.15B | $1.95B | $1.78B | $1.64B | +9.9% |
| Selling, general & admin | $2.08B | $1.83B | $1.51B | $1.28B | +13.7% |
| Total operating expense | $4.23B | $3.78B | $3.29B | $2.92B | +11.7% |
| Operating income | $447.14M | -$568.20M | -$1.21B | -$1.79B | +178.7% |
| Net interest income | $12.27M | $47.84M | $74.01M | $52.48M | -74.3% |
| Pre-tax income | $416.85M | -$533.00M | -$825.84M | -$1.96B | +178.2% |
| Tax provision | $129.92M | $111.78M | $55.87M | $42.78M | +16.2% |
| Net income | $286.93M | -$644.79M | -$881.71M | -$2.00B | +144.5% |
| Net income to common | $286.93M | -$644.79M | -$881.71M | -$2.00B | +144.5% |
| Basic EPS | 2.60 | -6.11 | -8.45 | -19.37 | +142.6% |
| Diluted EPS | 2.47 | -6.12 | -8.45 | -19.37 | +140.3% |
| EBIT | $475.09M | -$511.20M | -$821.47M | -$1.79B | +192.9% |
| EBITDA | $616.77M | -$339.43M | -$733.80M | -$1.72B | +281.7% |
| Basic shares | 109.06M | 105.29M | 104.39M | 103.13M | +3.6% |
| Diluted shares | 113.45M | 105.29M | 104.39M | 103.13M | +7.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $4.55B | $2.63B | $3.17B | $3.87B | +73.1% |
| Cash & short-term investments | $4.55B | $2.63B | $3.17B | $4.53B | +73.1% |
| Accounts receivable | $865.08M | $676.28M | $358.03M | $173.17M | +27.9% |
| Inventory | $608.23M | $494.99M | $416.12M | $282.35M | +22.9% |
| Total current assets | $6.23B | $3.99B | $4.20B | $5.21B | +56.2% |
| Property, plant & equipment | $1.72B | $1.64B | $1.37B | $923.98M | +4.3% |
| Goodwill & intangibles | $141.58M | $129.76M | $108.86M | $94.57M | +9.1% |
| Total assets | $8.19B | $5.92B | $5.81B | $6.38B | +38.3% |
| Total current liabilities | $1.83B | $2.21B | $1.81B | $1.47B | -17.4% |
| Current debt | $57.29M | $851.53M | $688.37M | $328.97M | -93.3% |
| Long-term debt | $961.91M | $166.48M | $197.62M | $209.15M | +477.8% |
| Total debt | $1.09B | $1.08B | $930.18M | $596.67M | +1.2% |
| Total liabilities | $3.83B | $2.59B | $2.27B | $2.00B | +47.9% |
| Retained earnings | -$8.32B | -$8.61B | -$7.96B | -$7.08B | +3.3% |
| Shareholder equity | $4.36B | $3.33B | $3.54B | $4.38B | +30.9% |
| Working capital | $4.40B | $1.78B | $2.39B | $3.74B | +147.9% |
| Net tangible assets | $4.22B | $3.20B | $3.43B | $4.29B | +31.8% |
| Shares issued | 1.54B | 1.38B | 1.35B | 1.36B | +11.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $286.93M | -$644.79M | -$881.71M | -$2.00B | +144.5% |
| Depreciation & amortisation | $141.69M | $171.76M | $87.67M | $66.28M | -17.5% |
| Stock-based compensation | $510.86M | $441.62M | $367.62M | $303.16M | +15.7% |
| Change in working capital | $190.90M | -$157.17M | -$370.54M | $132.39M | +221.5% |
| Operating cash flow | $1.13B | -$140.63M | -$1.16B | -$1.50B | +901.8% |
| Capital expenditure | -$266.53M | -$529.14M | -$596.26M | -$469.10M | +49.6% |
| Investing cash flow | -$276.15M | -$548.35M | $60.00M | $1.08B | +49.6% |
| Financing cash flow | $1.06B | $193.45M | $416.48M | -$18.97M | +447.7% |
| Free cash flow | $861.05M | -$669.77M | -$1.75B | -$1.97B | +228.6% |
| End cash position | $4.61B | $2.64B | $3.19B | $3.88B | +74.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $1.71B | $1.51B | $1.50B | $1.41B | $1.32B | +12.7% |
| Operating revenue | $2.23B | $1.89B | $1.96B | $1.77B | $1.67B | +17.7% |
| Cost of revenue | $174.53M | $167.22M | $142.42M | $196.51M | $164.61M | +4.4% |
| Gross profit | $1.53B | $1.35B | $1.36B | $1.22B | $1.15B | +13.7% |
| Research & development | $612.28M | $541.22M | $615.42M | $523.66M | $524.90M | +13.1% |
| Selling, general & admin | $593.21M | $555.10M | $555.29M | $529.00M | $537.91M | +6.9% |
| Total operating expense | $1.21B | $1.10B | $1.17B | $1.05B | $1.06B | +10.0% |
| Operating income | $325.05M | $249.90M | $185.03M | $163.11M | $87.89M | +30.1% |
| Net interest income | -$11.84M | -$5.22M | -$103.00K | $3.03M | $3.50M | -126.7% |
| Pre-tax income | $312.46M | $259.21M | $149.24M | $147.16M | $99.55M | +20.5% |
| Tax provision | $75.45M | $31.86M | $82.74M | $22.32M | $5.23M | +136.8% |
| Net income | $237.01M | $227.36M | $66.50M | $124.84M | $94.32M | +4.2% |
| Net income to common | $237.01M | $227.36M | $66.50M | $124.84M | $94.32M | +4.2% |
| Basic EPS | 2.08 | 2.08 | 0.65 | 1.17 | 0.91 | 0.0% |
| Diluted EPS | 2.08 | 1.95 | 0.52 | 1.04 | 0.78 | +6.7% |
| EBIT | $352.20M | $292.10M | $212.99M | $163.11M | $107.54M | +20.6% |
| EBITDA | $392.71M | $333.25M | $248.97M | $200.40M | $143.16M | +17.8% |
| Basic shares | 111.58M | 110.96M | 110.73M | 110.22M | 108.32M | +0.6% |
| Diluted shares | 115.80M | 115.77M | 115.38M | 114.52M | 112.56M | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.10B | $4.79B | $4.55B | $4.04B | $2.76B | +6.4% |
| Cash & short-term investments | $5.10B | $4.79B | $4.55B | $4.04B | $2.76B | +6.4% |
| Accounts receivable | $1.06B | $938.02M | $865.08M | $863.28M | $770.78M | +12.6% |
| Inventory | $732.60M | $681.59M | $608.23M | $531.69M | $502.87M | +7.5% |
| Total current assets | $7.22B | $6.60B | $6.23B | $5.66B | $4.31B | +9.3% |
| Property, plant & equipment | $1.79B | $1.79B | $1.72B | $1.77B | $1.77B | +0.3% |
| Goodwill & intangibles | $60.96M | $61.68M | $141.58M | $63.58M | $64.89M | -1.2% |
| Total assets | $9.18B | $8.55B | $8.19B | $7.63B | $6.30B | +7.3% |
| Total current liabilities | $2.12B | $1.81B | $1.83B | $2.37B | $2.21B | +17.0% |
| Current debt | $190.90M | $116.14M | $57.29M | $813.30M | $808.39M | +64.4% |
| Long-term debt | $882.16M | $962.51M | $961.91M | $139.57M | $146.09M | -8.3% |
| Total debt | $1.14B | $1.15B | $1.09B | $1.02B | $1.03B | -0.5% |
| Total liabilities | $4.00B | $3.79B | $3.83B | $3.50B | $2.53B | +5.5% |
| Retained earnings | -$7.86B | -$8.09B | -$8.32B | -$8.39B | -$8.51B | +2.9% |
| Shareholder equity | $5.17B | $4.76B | $4.36B | $4.13B | $3.77B | +8.7% |
| Working capital | $5.10B | $4.79B | $4.40B | $3.30B | $2.10B | +6.4% |
| Net tangible assets | $5.11B | $4.70B | $4.22B | $4.07B | $3.71B | +8.8% |
| Shares issued | 1.47B | 1.54B | 1.54B | 1.54B | 1.54B | -4.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $237.01M | $227.36M | $66.50M | $124.84M | $94.32M | +4.2% |
| Depreciation & amortisation | $40.52M | $41.14M | $35.98M | $37.28M | $35.61M | -1.5% |
| Stock-based compensation | $137.41M | $123.36M | $123.76M | $140.81M | $150.81M | +11.4% |
| Change in working capital | $69.75M | -$189.14M | $163.55M | $100.02M | $5.35M | +136.9% |
| Operating cash flow | $462.82M | $201.34M | $417.35M | $402.55M | $263.60M | +129.9% |
| Capital expenditure | -$47.99M | -$40.79M | -$37.52M | -$48.77M | -$63.83M | -17.7% |
| Investing cash flow | -$49.35M | -$45.51M | -$38.34M | -$49.27M | -$66.61M | -8.4% |
| Financing cash flow | -$6.05M | $68.63M | $96.93M | $961.27M | $35.02M | -108.8% |
| Free cash flow | $414.83M | $160.55M | $379.82M | $353.78M | $199.77M | +158.4% |
| End cash position | $5.28B | $4.85B | $4.61B | $4.11B | $2.79B | +8.8% |
Options analytics
Put / call volume
3.00
Put-heavy session
Put / call open interest
0.59
Positioning, not flow
Max pain
350.00
-3.8% from spot
ATM implied vol
41.9%
Nearest strike to spot
Skew (10% OTM)
-10.8%
Calls bid over puts
Call volume
29
Contracts, this expiry
Put volume
87
Contracts, this expiry
Heaviest call OI
310.00
38 contracts
Heaviest put OI
400.00
39 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 1.63 | 2.05 | +25.7% |
| Mar 2026 | 0.81 | 1.96 | +143.3% |
| Dec 2025 | 1.30 | 0.58 | -55.3% |
| Sep 2025 | 0.86 | 1.09 | +27.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 1.87 | 12 | $1.75B | +24.3% |
| Next quarter | 1.55 | 12 | $1.79B | +19.2% |
| Current year | 7.63 | 17 | $6.77B | +26.7% |
| Next year | 10.26 | 17 | $7.78B | +14.9% |
Analyst targets & ownership
Mean target$435.20
High target$528.00
Low target$370.00
Implied upside19.59%
Analyst count27
ConsensusSTRONG BUY
Strong buy / Buy7 / 20
Hold1
Sell / Strong sell0 / 0
Held by insiders17.28%
Held by institutions33.29%
Institutions holding390
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
362.42
+0.41% from price
SMA 20
358.20
+1.60% from price
SMA 50
355.43
+2.39% from price
SMA 100
324.15
+12.27% from price
SMA 200
320.95
+13.39% from price
EMA 12
361.55
+0.66% from price
EMA 26
358.95
+1.38% from price
EMA 50
350.87
+3.72% from price
RSI (14)
55.3
Neutral
MACD (12,26,9)
2.60
Hist -0.25
ATR (14)
9.28
2.55% of price
Realised vol 30D
22.8%
Annualised
Bollinger upper
373.72
20, 2σ
Bollinger lower
342.68
20, 2σ
50 / 200 cross
Golden
355.43 vs 320.95
Trend bias
Above 200
+13.39%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.85
Less volatile than market
Correlation to SPY
0.32
Loosely linked
Realised vol 30D
22.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-31.0%
Peak to trough
Max drawdown 5Y
-68.9%
Peak to trough
ATR 14
9.28
2.55% of price
Beta (reported)
0.61
5Y monthly, from filing
Short interest
Shares short
1.71M
Prior 1.28M
Change vs prior
+33.8%
Shorts adding
% of float
2.11%
Normal
% of shares out
1.50%
Against total outstanding
Days to cover
4.7
Liquid
Float
80.96M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 7, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Oct 1, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Sep 10, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Aug 6, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Aug 6, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Aug 6, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Aug 6, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 6, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Aug 6, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Jul 23, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Jul 14, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Jul 13, 26 | Jefferies | UPGRADE | Hold | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-26
Periodic Financial Reports
10-Q · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-06-26
Offering Registrations
S-8 · 2026-06-11
Corporate Changes & Voting Matters
8-K · 2026-05-15
Offering Registrations
S-3ASR · 2026-05-06
Annual Report to Shareholders
ARS · 2026-04-28
Proxy Statements
PRE 14A · 2026-04-16
Headlines
Biotech Leader BeOne Medicines Poised To Hit Early Buy Points
Investor's Business Daily · 6d ago
BeOne Medicines (ONC) Stock May Be Fully Priced After An 86% Run
Simply Wall St. · 32d ago
The Bull Case For BeOne Medicines (ONC) Could Change Following US-Backed HER2 Regimen And Onshoring Deal
Simply Wall St. · 33d ago
BeOne (ONC) Secured a Pharmaceutical-Tariff Exemption After More than $1B of U.S. Manufacturing Investment. Are the Pricing Concessions Worth It?
Insider Monkey · 33d ago
FDA Approval Marks A Turning Point For BeOne Medicines (ONC)
Insider Monkey · 36d ago
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
Zacks · 36d ago
BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
Business Wire · 36d ago
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
Business Wire · 37d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.